Welcome!
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
Dr. David Harpole, Duke University Medical Center, describes how he assists patients with the surgical decision-making process.
Transcript
As a thoracic surgeon, we are the physicians that a lot of patients come to with lung cancer. Unfortunately, the outcomes for lung cancer have not been great, and I would say that there are some physicians that are surgeons where the patients come to them and are wary and don’t want surgery. It’s pretty much the opposite in lung cancer, most patients know that if we’re able to take the tumor out, that’s their best chance for survival.
So the first thing I do when patients come to us is reassure them that we need to adequately assess their strength and so forth for surgery, detail the extent of their disease which often involves not just surgeons but a medical oncologist, a radiation oncologist and an interventional pulmonologist in our practice. We discuss the fact that lung cancer is not treated with any one hammer — I usually say I use two or three different hammers depending on which modality we’re going to take on. Then at the location of their mass, we’ll take pictures from their CT scan and show it to them and discuss what are the surgical options, whether it’s something small that we can do with video-assisted techniques, or is it something that’s going to require quite a bit larger operation, then we discuss those with them.
I have a rule in my practice that I never let a patient decide on their care the very first visit that we have. We always want them and their family to spend time thinking about it, read the materials, then they come back and we decide on the best course of treatment. It’s an awful lot that comes at you when you’ve had the diagnosis of lung cancer and I feel like a judicious, slow approach is the thing that most patients appreciate from their physicians.
Please feel free to offer comments and raise questions in our
discussion forums.
Bispecifics, or bispecific antibodies, are advanced immunotherapy drugs engineered to have two binding sites, allowing them to latch onto two different targets simultaneously, like a cancer cell and a T-cell, effectively...
The prefix “oligo–” means few. Oligometastatic (at diagnosis) Oligoprogression (during treatment)
There will be a discussion, “Studies in Oligometastatic NSCLC: Current Data and Definitions,” which will focus on what we...
Radiation therapy is primarily a localized treatment, meaning it precisely targets a specific tumor or area of the body, unlike systemic treatments (like chemotherapy) that affect the whole body.
The...
Biomarkers are genetic mutations (like EGFR, ALK, KRAS, BRAF) or protein levels (like PD-L1) in tumor cells that help guide personalized treatment, especially NSCLC, directing patients to targeted therapies or immunotherapies...
Hi Stan! So good to hear from you. I'm sorry for the late response. I too have been out of town with family and missed your post, probably because I was...
It is so good to hear from you! And I am so happy to hear that your holidays have been good and that you are doing well. It sounds like your...
Welcome to the new CancerGRACE.org! Explore our fresh look and improved features—take a quick tour to see what’s new.
An antibody–drug conjugate (ADC) works a bit like a Trojan horse. It has three main components: